| 1 |
Berek JS, Renz M, Friedlander ML, Bast RC. Nonepithelial Ovarian Malignancies. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm106.pub2] [Reference Citation Analysis]
|
| 2 |
Tranoulis A, Fernando IN. Hormonal Treatment in Gynaecological Malignancies. Gynecological Oncology 2022. [DOI: 10.1007/978-3-030-94110-9_12] [Reference Citation Analysis]
|
| 3 |
Banerjee SN, Tang M, O'Connell RL, Sjoquist K, Clamp AR, Millan D, Nottley S, Lord R, Mullassery VM, Hall M, Gourley C, Bonaventura T, Goh JC, Sykes P, Grant PT, McNally O, Alexander L, Kelly C, Carty K, Divers L, Bradshaw N, Edmondson RJ, Friedlander M; PARAGON investigators. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. Gynecol Oncol 2021;163:72-8. [PMID: 34412908 DOI: 10.1016/j.ygyno.2021.07.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 4 |
Friedlander M, Benson C, O'Connell RL, Reed N, Clamp A, Lord R, Millan D, Nottley S, Amant F, Steer C, Anand A, Mileshkin L, Beale P, Banerjee S, Bradshaw N, Kelly C, Carty K, Divers L, Alexander L, Edmondson R. Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecol Oncol 2021;161:160-5. [PMID: 33608144 DOI: 10.1016/j.ygyno.2021.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 5 |
Ponandai-Srinivasan S, Lalitkumar PG, Garcia L, Varghese SJ, Carlson JW, Gemzell-Danielsson K, Floter Radestad A. Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1-/2- carriers. Acta Obstet Gynecol Scand 2019;98:250-61. [PMID: 30325501 DOI: 10.1111/aogs.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 6 |
Park J, Baek M, Park Y, Kim Y, Nam J. Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma. Virchows Arch 2018;473:61-9. [DOI: 10.1007/s00428-018-2358-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 7 |
Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. Int J Gynecol Cancer 2017;27:900-6. [PMID: 28498256 DOI: 10.1097/IGC.0000000000000978] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 8 |
Taube ET, Denkert C, Sehouli J, Unger U, Kunze CA, Budczies J, Dietel M, Braicu E, Darb-Esfahani S. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma. Hum Pathol 2017;67:30-6. [PMID: 28414091 DOI: 10.1016/j.humpath.2017.03.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 9 |
Rambau P, Kelemen LE, Steed H, Quan ML, Ghatage P, Köbel M. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. Int J Mol Sci 2017;18:E515. [PMID: 28264438 DOI: 10.3390/ijms18030515] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 10 |
Berek JS, Friedlander ML, Bast RC. Nonepithelial Ovarian Malignancies. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm106] [Reference Citation Analysis]
|
| 11 |
Garbi A, Achilarre MT, Colombo N. Ovarian Sex Cord Tumors. Ovarian Cancers 2017. [DOI: 10.1007/978-3-319-32110-3_19] [Reference Citation Analysis]
|
| 12 |
Rezvanpour A, Don-wauchope AC. Clinical implications of estrone sulfate measurement in laboratory medicine. Critical Reviews in Clinical Laboratory Sciences 2016;54:73-86. [DOI: 10.1080/10408363.2016.1252310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 13 |
Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer 2015;25:1565-73. [PMID: 26495758 DOI: 10.1097/IGC.0000000000000553] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 14 |
Battista MJ, Schmidt M. Fulvestrant for the treatment of endometrial cancer. Expert Opin Investig Drugs 2016;25:475-83. [PMID: 26882357 DOI: 10.1517/13543784.2016.1154532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 15 |
Battista MJ, Stickeler E, Schmidt M. Prädiktive Faktoren in der metastasierten Situation. Gynäkologe 2015;48:885-90. [DOI: 10.1007/s00129-015-3803-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 16 |
Romano G. Tumor markers currently utilized in cancer care. MATER METHODS 2015;5. [DOI: 10.13070/mm.en.5.1456] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 17 |
Wolfe H, Bunch K, Stany M. Prolonged response to exemestane following multiple surgical resections and hormonal therapies in a patient with recurrent endometrial stromal sarcoma. Gynecol Oncol Rep 2016;15:4-6. [PMID: 26937477 DOI: 10.1016/j.gore.2015.07.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 18 |
Battista MJ, Schmidt M, Eichbaum M, Almstedt K, Heimes AS, Mallmann P, Hoffmann G, Steiner E. Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Arch Gynecol Obstet 2015;292:1355-60. [PMID: 26099624 DOI: 10.1007/s00404-015-3786-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 19 |
François CM, Wargnier R, Petit F, Goulvent T, Rimokh R, Treilleux I, Ray-Coquard I, Zazzu V, Cohen-Tannoudji J, Guigon CJ. 17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. Carcinogenesis 2015;36:564-73. [PMID: 25823895 DOI: 10.1093/carcin/bgv041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 20 |
van Meurs HS, van Lonkhuijzen LR, Limpens J, van der Velden J, Buist MR. Hormone therapy in ovarian granulosa cell tumors: A systematic review. Gynecologic Oncology 2014;134:196-205. [DOI: 10.1016/j.ygyno.2014.03.573] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 7.2] [Reference Citation Analysis]
|
